 FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome SBS using Total Stool Output TSO as a primary efficacy outcome measure Announced positive topline data in December for NM-002, a proprietary long-acting GLP-1, in a Phase 1b2a trial for SBS Companys RD day on March 23rd to include additional Phase 1b2a study data on parenteral support, pharmacokinetics and quality of life Phase 3 interim analysis and topline data for larazotide in celiac disease now anticipated in 2022 due to COVID-19 impact on patient enrollment Raised over 58 million from prominent institutional healthcare investors in 2020 Research Development Day on Short Bowel Syndrome planned for tomorrow March 23rd at 11:00 AM ET - see for registration details RALEIGH, NC ACCESSWIRE March 22, 2021 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage rare and unmet needs-focused gastroenterology company, today provided an overview of its recent achievements and 2021 outlook and reported its financial results for the fourth quarter and full year ended December 31, 2020. Full Year Recent Business Highlights After a recent productive FDA interaction in Q1 2021, the Company plans to move forward using total stool output TSO as the primary efficacy endpoint in an upcoming Phase 2 trial, which we plan to begin in Q2 and report final data in Q4. 